ReNerve (ASX: RNV) received an additional AU$139,537 in research and development tax incentives following an assessment of the company's overseas research activities, bringing its total refund to AU$516,606, according to a Friday filing with the Australian bourse.
The company said it is working and developing products aimed to provide a complete range of products for peripheral nerve repair and replacement.
The company's shares were down almost 4% in recent Friday trade, earlier hitting an all-time low.